Arasertaconazole

Drug Profile

Arasertaconazole

Alternative Names: Arasertaconazole nitrate

Latest Information Update: 15 Jan 2016

Price : $50

At a glance

  • Originator Ferrer
  • Class Antifungals
  • Mechanism of Action Sterol demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Vulvovaginal candidiasis

Most Recent Events

  • 15 Jan 2016 Ferrer plans a phase III trial for Vulvovaginal candidiasis in Spain (Ferrer pipeline, January 2016)
  • 14 Dec 2015 Arasertaconazole is ready to enter phase III development for vulvovaginal candidiasis
  • 13 May 2013 Arasertaconazole is available for licensing as of 08 May 2013. http://www.ferrergrupo.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top